Elevate your local knowledge
Sign up for the iNFOnews newsletter today!
Actavis to spend $66 billion on Botox-maker Allergan, which has fought takeover by Valeant
Original Publication Date: November 16, 2014 10:33PM
Publication Updated: January 8, 2025 9:32PM
Actavis is paying $66 billion to buy fellow drugmaker Allergan in a deal that could finally end a months-long takeover battle waged by Valeant Pharmaceuticals for the Botox maker.
Actavis said Monday that it will spend $219 in cash and stock for each share of Allergan.
That tops a bid for Allergan valued at about $53 billion and made last spring by Valeant Pharmaceuticals International Inc. and the hedge fund Pershing Square Capital Management. That offer totalled about $179 in cash and stock.
Allergan resisted the Valeant deal for months, but its board has unanimously approved the Actavis offer.
News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.
Join the Conversation!
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.
